|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Business Insight & Analytics specialist
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°æ¿µ/Àü·«±âȹ/ÄÁ¼³Æà |
5³â¡è |
ä¿ë½Ã |
09.27 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Patient Advocacy Head
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°æ¿µ/Àü·«±âȹ/ÄÁ¼³Æà |
10³â¡è |
ä¿ë½Ã |
05.20 |
|
|
Å©¸®½ºÅ»Áö³ë¹Í½º(ÁÖ) |
»ç¾÷°³¹ß ¹× ¿¬±¸±âȹ °æ·ÂÁ÷ ä¿ë
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
3³â¡è |
ä¿ë½Ã |
09.20 |
|
|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
[LSK Global PS] DM Manager (Global Study Dedicated DM)
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
STAT/DM |
5³â¡è |
ä¿ë½Ã |
04.22 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] MSL, Dupilumab
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
3³â¡è |
ä¿ë½Ã |
10.18 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Field medical, Dupilumab (Medical manage
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
10³â¡è |
ä¿ë½Ã |
10.18 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Field medical, Dupilumab (Medical manage
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
10³â¡è |
ä¿ë½Ã |
10.17 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] District Sales Manager, Respiratory
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
7³â¡è |
ä¿ë½Ã |
10.18 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Dupixient Product Manager, Respiratory
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
5³â¡è |
ä¿ë½Ã |
10.18 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] RA Specialist
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
4³â¡è |
ä¿ë½Ã |
10.18 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Dupixient Product Manager, Respiratory
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
5³â¡è |
ä¿ë½Ã |
10.21 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] RA Specialist
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
4³â¡è |
ä¿ë½Ã |
10.21 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Business Insight & Analytics specialist
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°æ¿µ/Àü·«±âȹ/ÄÁ¼³Æà |
5³â¡è |
ä¿ë½Ã |
10.18 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] RENVELA Product Manager
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
5³â¡è |
ä¿ë½Ã |
10.18 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] MSL, Dupilumab
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
3³â¡è |
ä¿ë½Ã |
10.17 |
|